EUVIMEDEUVIMED entdecken
Übersichtsarbeit

TGFBI: A novel therapeutic target for cancer

Huimei Huang, Qinglai Tang, Shisheng Li, Yuexiang Qin, Gangcai Zhu

International Immunopharmacology · 2024-06 · 134 · 112180

DOI: 10.1016/j.intimp.2024.112180 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2024-06. Verfasst von Huimei Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Neoplasms, Tumor Microenvironment, Transforming Growth Factor beta. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 94 Literaturangaben. Gefördert von: Health Commission of Hunan Province, National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TGFBI, an extracellular matrix protein induced by transforming growth factor β, has been found to exhibit aberrant expression in various types of cancer. TGFBI plays a crucial role in tumor cell proliferation, angiogenesis, and apoptosis. It also facilitates invasion and metastasis in various types of cancer, including colon, head and neck squamous, renal, and prostate cancers. TGFBI, a prominent p-EMT marker, strongly correlates with lymph node metastasis. TGFBI demonstrates immunosuppressive effects within the tumor immune microenvironment. Targeted therapy directed at TGFBI shows promise as a potential strategy to combat cancer. Hence, a comprehensive review was conducted to examine the impact of TGFBI on various aspects of tumor biology, including cell proliferation, angiogenesis, invasion, metastasis, apoptosis, and the immune microenvironment. This review also delved into the underlying biochemical mechanisms to enhance our understanding of the research advancements related to TGFBI in the context of tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsTumor MicroenvironmentTransforming Growth Factor betaHumansAnimalsMolecular Targeted TherapyExtracellular Matrix ProteinsNeovascularization, PathologicApoptosisCell ProliferationAntineoplastic Agents

Stichwörter der Autor:innen

CancerImmune microenvironmentMetastasisTGFBI

Substanzen

Transforming Growth Factor betaExtracellular Matrix ProteinsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Department of Otolaryngology-Head and Neck Surgery, The Third Xiangya Hospital, Central South University, Changsha, China.
  • Department of Otolaryngology-Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, China. Electronic address: qianhudoctor@csu.edu.cn.

Förderung

  • Health Commission of Hunan Province
  • National Natural Science Foundation of China
  • Natural Science Foundation of Hunan Province
  • China Postdoctoral Science Foundation
  • Science and Technology Program of Hunan Province

Zitieren

APA

Huang, H., Tang, Q., Li, S., Qin, Y., & Zhu, G. (2024). TGFBI: A novel therapeutic target for cancer. International Immunopharmacology, 134, 112180. https://doi.org/10.1016/j.intimp.2024.112180

Vancouver

Huang H, Tang Q, Li S, Qin Y, Zhu G. TGFBI: A novel therapeutic target for cancer. International Immunopharmacology. 2024;134:112180. doi:10.1016/j.intimp.2024.112180

BibTeX
@article{Huang2024,
  author = {Huang, Huimei and Tang, Qinglai and Li, Shisheng and Qin, Yuexiang and Zhu, Gangcai},
  title = {TGFBI: A novel therapeutic target for cancer},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {134},
  pages = {112180},
  doi = {10.1016/j.intimp.2024.112180}
}
Kostenlos starten →